The 229 references in paper A. Smirnov V., M. Volkov M., V. Dobronravov A., А. Смирнов В., М. Волков М., В. Добронравов А. (2009) “ЗНАЧИМОСТЬ ЦИНАКАЛЬЦЕТА В КОРРЕКЦИИ НАРУШЕНИЙ ФОСФОРНО-КАЛЬЦИЕВОГО БАЛАНСА У БОЛЬНЫХ С ХРОНИЧЕСКОЙ БОЛЕЗНЬЮ ПОЧЕК // THE SIGNIFICANCE OF CINACALCET IN CORRECTION OF PHOSPHORUS-CALCIUM DISBALANCE IN PATENTS WITH CHRONIC KIDNEY DISEASE” / spz:neicon:nefr:y:2009:i:2:p:15-34

1
Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31(4):607-617
(check this in PDF content)
2
Ganesh SK, Stack AG, Levin NW et al. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12(10):2131-2138
(check this in PDF content)
3
Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359(6):584-592
(check this in PDF content)
4
Negri AL. Association of oral calcitriol with improved survival in non-dialysed and dialysed patients with CKD. Nephrol Dial Transplant 2009;24(2):341-344
(check this in PDF content)
5
Teng M, Wolf M, Lowrie E et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349(5):446-456
(check this in PDF content)
6
Shoji T, Shinohara K, Kimoto E et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19(1):179-184
(check this in PDF content)
7
Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar- Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168(4):397-403
(check this in PDF content)
8
Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38(4):938-942
(check this in PDF content)
9
Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342(20):1478-1483
(check this in PDF content)
10
Proudfoot D, Shanahan CM. Biology of calcification in vascular cells: intima versus media. Herz 2001;26(4):245-251
(check this in PDF content)
11
Edmonds ME. Medial arterial calcification and diabetes mellitus. Z Kardiol 2000;89 Suppl 2:101-104
(check this in PDF content)
12
London GM, Drueke TB. Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 1997; 51(6): 1678-1695
(check this in PDF content)
13
Diehm C, Kareem S, Lawall H. Epidemiology of peripheral arterial disease. Vasa 2004;33(4):183-189
(check this in PDF content)
14
Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcification in end-stage renal disease. Nephr Dial Transpl 2000;15:1014-1021
(check this in PDF content)
15
Bro S, Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis 1997;30(5):606-620
(check this in PDF content)
16
Cunningham J. Are parathyroidectomies still appropriate in chronic dialysis patients? Semin Dial 2000; 13(5): 275-278
(check this in PDF content)
17
Hruska KA, Saab G, Mathew S, Lund R. Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial 2007;20(4):309-315
(check this in PDF content)
18
Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, Calcium, and phosphorua in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 2007;71:31-38
(check this in PDF content)
19
Wang Y, Sun Z. Current understanding of klotho. Ageing Res Rev 2008 Oct 31 [Epub ahead of print]
(check this in PDF content)
20
Torres PU, Prie D, Beck L et al. Klotho gene, phosphocalcic metabolism, and survival in dialysis. J Ren Nutr 2009;19(1):50-56
(check this in PDF content)
21
Wetmore JB, Quarles LD. Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift? Nat Clin Pract Nephrol 2009;5(1):24-33
(check this in PDF content)
22
Urakawa I, Yamazaki Y, Shimada T et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006;444(7120):770-774
(check this in PDF content)
23
Kuro-o M, Matsumura Y, Aizawa H et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390(6655):45-51
(check this in PDF content)
24
Koh N, Fujimori T, Nishiguchi S et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001;280(4):1015-1020
(check this in PDF content)
25
Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 2007;20(4):302-308
(check this in PDF content)
26
Fukagawa M, Kazama JJ. FGF23: its role in renal bone disease. Pediatr Nephrol 2006;21(12):1802-1806
(check this in PDF content)
27
Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359(6):584-592
(check this in PDF content)
28
Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005; 288(2): F253-264
(check this in PDF content)
29
Fukuda N, Tanaka H, Tominaga Y et al. Decreased 1,25- dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993;92(3):1436-1443
(check this in PDF content)
30
Kifor O, Moore FD Jr, Wang P et al. Reduced immunostaining for the extracellular Ca2+-sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996;81(4):1598-1606
(check this in PDF content)
31
Gogusev J, Duchambon P, Hory B et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997;51(1):328-336
(check this in PDF content)
32
Craver L, Marco MP, Martinez I et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5— achievement of K/DOQI target ranges. Nephrol Dial Transplant 2007;22(4):1171-1176
(check this in PDF content)
33
Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005;16(7):2205-2215
(check this in PDF content)
34
Berndt T, Kumar R. Phosphatonins and the regulation of phosphate homeostasis. Annu Rev Physiol 2007;69:341-359
(check this in PDF content)
35
Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007;18(6):1637-1647
(check this in PDF content)
36
Shigematsu T, Kazama JJ, Yamashita et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004;44(2):250-256
(check this in PDF content)
37
Shimada T, Hasegawa H, Yamazaki Y et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19(3):429-435
(check this in PDF content)
38
Coburn JW, Popovtzer MM, Massry SG, Kleeman CR. The physicochemical state and renal handling of divalent ions in chronic renal failure. Arch Intern Med 1969;124(3):302-311
(check this in PDF content)
39
Coburn JW, Koppel MH, Brickman AS, Massry SG. Study of intestinal absorption of calcium in patients with renal failure. Kidney Int 1973;3(4):264-272
(check this in PDF content)
40
Popovtzer MM, Schainuck LI, Massry SG, Kleeman CR. Divalent ion excretion in chronic kidney disease: relation to degree of renal insufficiency. Clin Sci 1970;38(3):297-307
(check this in PDF content)
41
Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int 2008; 74(3):276-288
(check this in PDF content)
42
Bricker NS. On the pathogenesis of the uremic state. An exposition of the «trade-off hypothesis». N Engl J Med 1972; 286(20):1093-1099
(check this in PDF content)
43
Slatopolsky E, Bricker NS. The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int 1973;4(2):141-145
(check this in PDF content)
44
Kohlhagen J, Kelly J. Prevalence of vascular risk factors and vascular disease in predialysis chronic renal failure. Nephrology (Carlton) 2003;8(6):274-279
(check this in PDF content)
45
Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16(2):520-528
(check this in PDF content)
46
Voormolen N, Noordzij M, Grootendorst DC et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007;22(10):2909-2916
(check this in PDF content)
47
Kuro-o M. Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens 2006;15(4):437-441
(check this in PDF content)
48
Morishita K, Shirai A, Kubota M et al. The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr 2001;131(12):3182-3188
(check this in PDF content)
49
Волков ММ, Дегтерева ОА, Шевякова ЕВ. Факторы, связанные с кальцинацией клапанного аппарата сердца у пациентов на хроническом гемодиализе. Нефрология 2007;11(3):57-63
(check this in PDF content)
50
Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm 2007; 13(5): 397-411
(check this in PDF content)
51
Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15(8):2208-2218
(check this in PDF content)
52
Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar- Zadeh K. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int 2008;73(11):1296-1302
(check this in PDF content)
53
Covic A, Kothawala P, Bernal M et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2008 Nov 11. [Epub ahead of print]
(check this in PDF content)
54
Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008;52(3):519-530
(check this in PDF content)
55
Moe SM. Vascular calcification and renal osteodystrophy relationship in chronic kidney disease. Eur J Clin Invest 2006; 36 (Suppl 2):51-62
(check this in PDF content)
56
Wang AY, Woo J, Wang M et al. Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 2001;12(9):1927-1936.
(check this in PDF content)
57
Nasri H, Baradaran A. Close Association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis. J Ayub Med Coll Abbottabad 2004;16(2): 3-8
(check this in PDF content)
58
Lemmila S, Saha H, Virtanen V et al. Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis. Am J Nephrol 1998;18(5):404-410
(check this in PDF content)
59
Wanic-Kossowska M, Lehmann P, Czekalski S. Left ventricular systolic and diastolic dysfunction in patients with chronic renal failure treated with hemodialysis. Pol Arch Med Wewn 2003;109(4):365-373
(check this in PDF content)
60
Kostic S, Veljkovic S, Cekic S et al. The effect of parathormone on arterial blood pressure in patients on hemodialysis. Srp Arh Celok Lek 1996;124 [Suppl 1]:115-116
(check this in PDF content)
61
Jorde R, Svartberg J, Sundsfjord J. Serum parathyroid hormone as a predictor of increase in systolic blood pressure in men. J Hypertens 2005;23(9):1639-1644
(check this in PDF content)
62
Letizia C, Ferrari P, Cotesta D et al. Ambulatory monitoring of blood pressure (AMBP) in patients with primary hyperparathyroidism. J Hum Hypertens 2005;19(11): 901-906
(check this in PDF content)
63
Dalberg K, Brodin LA, Juhlin-Dannfelt A, Farnebo LO. Cardiac function in primary hyperparathyroidism before and after operation. An echocardiographic study. Eur J Surg 1996; 162(3):171-176
(check this in PDF content)
64
Evenepoel P, Claes K, Kuypers D et al. Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrol Dial Transplant 2005; 20(8):1714-1720
(check this in PDF content)
65
Pajda M, Matug A, Widlak M et al. Influence of parathyroidectomy on blood pressure and function of the transplanted kidney in patients with tertiary hyperparathyroidism. Ann Transplant 2006;11(1):11-15
(check this in PDF content)
66
Iqbal A, Jorde R, Lunde P et al. Left ventricular dysfunction in subjects with mild secondary hyperparathyroidism detected with pulsed wave tissue Doppler echocardiography. Cardiology 2006;105(1):1-8.
(check this in PDF content)
67
Волков ММ, Смирнов АВ, Дегтерева ОА, Шевякова ЕВ. Дисфункции миокарда, оцениваемые методом ткане­ вой допплерографии и фосфорно-кальциевый баланс у пациентов на хроническом гемодиализе. Нефрология 2008; 12(3):18-23
(check this in PDF content)
68
Goto N, Tominaga Y, Matsuoka S et al. Cardiovascular complications caused by advanced secondary hyperparathyroidism in chronic dialysis patients; special focus on dilated cardiomyopathy. Clin Exp Nephrol 2005; 9(2):138-141
(check this in PDF content)
69
Ohara N, Hiramatsu K, Shigematsu S et al. Effect of parathyroid hormone on left ventricular diastolic function in patients with primary hyperparathyroidism. Miner Electrolyte Metab 1995; 21(1-3):63-66
(check this in PDF content)
70
National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis (2003) 42:S1-S201
(check this in PDF content)
71
Fukagawa M, Okazaki R, Takano K et al. Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med 1990;323(6):421-422
(check this in PDF content)
72
Gallieni M, Brancaccio D, Padovese P et al. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int 1992; 42(5): 1191-1198
(check this in PDF content)
73
Tan AU Jr, Levine BS, Mazess RB et al. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997;51(1):317-323
(check this in PDF content)
74
Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62(1):245-252
(check this in PDF content)
75
McCullough PA, Sandberg KR, Dumler F, Yanez JE. Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review. J Nephrol 2004;17(2):205-215
(check this in PDF content)
76
Tominaga Y, Inaguma D, Matsuoka S et al. Is the volume of the parathyroid gland a predictor of Maxacalcitol response in advanced secondary hyperparathyroidism? Ther Apher Dial 2006;10(2):198-204
(check this in PDF content)
77
Bas A, Lopez I, Perez J et al. Reversibility of calcitriol- induced medial artery calcification in rats with intact renal function. J Bone Miner Res 2006;21(3):484-490
(check this in PDF content)
78
Niederhoffer N, Bobryshev YV, Lartaud-Idjouadiene I et al. Aortic calcification produced by vitamin D3 plus nicotine. J Vasc Res 1997;34(5):386-398
(check this in PDF content)
79
Brown EM, Gamba G, Riccardi D et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993;366(6455):575-580
(check this in PDF content)
80
DruekeTB. Modulation and action of the calcium-sensing receptor. Nephrol Dial Transplant 2004;19 Suppl 5:V20-26
(check this in PDF content)
81
Nagano N, Nemeth EF. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics. J Pharmacol Sci 2005;97(3):355-360
(check this in PDF content)
82
DruekeTB. Modulation and action of the calcium-sensing receptor. Nephrol Dial Transplant 2004;19 Suppl 5:V20-V26
(check this in PDF content)
83
Levi R, Ben-Dov IZ, Lavi-Moshayoff V et al. Increased Parathyroid Hormone Gene Expression in Secondary Hyperparathyroidism of Experimental Uremia Is Reversed by Calcimimetics: Correlation with Posttranslational Modification of the Trans Acting Factor AUF1. J Am Soc Nephrol 2006; 17(1): 107-112
(check this in PDF content)
84
Rodriguez ME, Almaden Y, Canadillas S et al. The calcimimetic R-568 increases vitamin D receptor expression in rat parathyroid glands. Am J Physiol Renal Physiol 2007; 292(5): F1390-1395
(check this in PDF content)
85
Huang C, Miller RT. Regulation of renal ion transport by the calcium-sensing receptor: an update. Curr Opin Nephrol Hypertens 2007;16(5):437-443
(check this in PDF content)
86
Smajilovic S, Tfelt-Hansen J. Calcium acts as a first messenger through the calcium-sensing receptor in the cardiovascular system. Cardiovasc Res 2007;75(3):457-467
(check this in PDF content)
87
Tfelt-Hansen J, Brown EM. The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit Rev Clin Lab Sci 2005;42(1):35-70
(check this in PDF content)
88
Goodman WG, Hladik GA, Turner SA et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002;13(4):1017-1024
(check this in PDF content)
89
Shoback DM, Bilezikian JP, Turner SA et al. The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism. J Clin Endocrinol Metab 2003; 88(12):5644-5649
(check this in PDF content)
90
Quarles LD, Sherrard DJ, Adler S et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003;14(3):575-583
(check this in PDF content)
91
Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350(15):1516-1525
(check this in PDF content)
92
Peacock M, Bilezikian JP, Klassen PS et al. Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 2005; 90(1):135-141
(check this in PDF content)
93
Moe SM, Cunningham J, Bommer J et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005; 20(10):2186-2193
(check this in PDF content)
94
Lindberg JS, Culleton B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol 2005;16(3):800-807
(check this in PDF content)
95
Chertow GM, Blumenthal S, Turner S et al. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate. Clin J Am Soc Nephrol 2006;1(2):305-312
(check this in PDF content)
96
Fukagawa M, Yumita S, Akizawa T et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 2008;23(1):328-335
(check this in PDF content)
97
Messa P, Macario F, Yaqoob M et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008;3(1):36-45
(check this in PDF content)
98
Evenepoel P Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. Kidney Int 2008; 74(3): 265-275
(check this in PDF content)
99
Nagano N. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther 2006;109(3):339-365
(check this in PDF content)
100
Moe SM, Chertow GM, Coburn JW et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005;67(2):760-771
(check this in PDF content)
101
Arenas MD, Alvarez-Ude F, Gil MT et al. Implementation of ‘K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease’ after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transplant 2007;22(6):1639-1644
(check this in PDF content)
102
Coen G, Calabria S, Bellinghieri G et al. Parathyroidectomy in chronic renal failure: short- and long­ term results on parathyroid function, blood pressure and anemia. Nephron 2001;88(2):149-155
(check this in PDF content)
103
Saunders RN, Karoo R, Metcalfe MS, Nicholson ML. Four gland parathyroidectomy without reimplantation in patients with chronic renal failure. Postgrad Med J 2005;81(954):255- 258
(check this in PDF content)
104
Parfitt AM. Hypercalcemic hyperparathyroidism following renal transplantation: differential diagnosis, management, and implications for cell population control in the parathyroid gland. Miner Electrolyte Metab 1982;8(2):92-112
(check this in PDF content)
105
Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int Suppl 2006;(102):S3-7
(check this in PDF content)
106
Tominaga Y, TanakaYet al. Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997;13:78-86
(check this in PDF content)
107
Drueke T, Martin D, Rodriguez M. Can calcimimetics inhibit parathyroid hyperplasia? Evidence from preclinical studies. Nephrol Dial Transplant 2007;22(7):1828-1839
(check this in PDF content)
108
Wada M, Furuya Y, Sakiyama J et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997;100(12):2977-2983
(check this in PDF content)
109
Colloton M, Shatzen E, Miller G et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005;67(2):467-476
(check this in PDF content)
110
Mizobuchi M, Ogata H, Hatamura I et al. Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells. Biochem Biophys Res Commun 2007;362(1):11-16
(check this in PDF content)
111
Meola M, Petrucci I, Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 2009;24(3):982-989
(check this in PDF content)
112
Komaba H, Fukagawa M. Regression of parathyroid hyperplasia by calcimimetics—fact or illusion? Nephrol Dial Transplant 2009;24(3):707-709
(check this in PDF content)
113
Terawaki H, Nakano H, Takeguchi F et al. Regression of parathyroid gland swelling by treatment with cinacalcet. Nephrol Dial Transplant 2008;23(1):328-335
(check this in PDF content)
114
Chin J, Miller SC, Wada M et al. Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. J Am Soc Nephrol 2000;11(5):903-911
(check this in PDF content)
115
Mizobuchi M, Hatamura I, Ogata H et al. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 2004;15(10):2579-2587
(check this in PDF content)
116
Cunningham J, Danese M, Olson K et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68(4):1793-1800
(check this in PDF content)
117
Jadoul M, Albert JM, Akiba T et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006;70(7):1358-1366
(check this in PDF content)
118
Alem AM, Sherrard DJ, Gillen DL et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000;58(1):396-399
(check this in PDF content)
119
Jadoul M. Towards the prevention of bone fractures in dialysed patients? Nephrol Dial Transplant 2007;22(12):3377-3380
(check this in PDF content)
120
Wada M, Ishii H, Furuya Y et al. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1998; 53(2): 448-453
(check this in PDF content)
121
Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2005;20(6):1232- 1237
(check this in PDF content)
122
Добронравов ВА, Волков ММ, Мнускина ММ и др. Фосфорно-кальциевый баланс и минеральная плотность костей различных отделов скелета у больных на хроничес­ ком гемодиализе. Нефрология 2006; 10(4):31-36
(check this in PDF content)
123
Kawata T, Nagano N, Obi M et al. Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int 2008;74(10):1229-1231
(check this in PDF content)
124
Malluche HH, Monier-Faugere MC, Wang G et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 2008;69(4):269-278
(check this in PDF content)
125
Sherrard DJ, Hercz G, Pei Y et al. The spectrum of bone disease in end-stage renal failure—an evolving disorder. Kidney Int 1993;43(2):436-442
(check this in PDF content)
126
Mucsi I, Hercz G. Relative hypoparathyroidism and adynamic bone disease. Am J Med Sci 1999;317(6):405-409
(check this in PDF content)
127
Couttenye MM, D’Haese PC, Van Hoof VO et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996;11(6):1065-1072
(check this in PDF content)
128
Spasovski GB, Bervoets AR, Behets GJ et al. Nephrol Dial Transplant 2003;18(6):1159-1166
(check this in PDF content)
129
Pei Y, Hercz G, Greenwood C et al. Risk factors for renal osteodystrophy: a multivariant analysis. J Bone Miner Res 1995;10(1):149-156
(check this in PDF content)
130
Qi Q, Monier-Faugere MC, Geng Z, Malluche HH. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995;26(4):622-631
(check this in PDF content)
131
Malluche HH, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int Suppl 1992;38:S62-67
(check this in PDF content)
132
London GM, Marty C, Marchais SJ et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004;15(7):1943-1951
(check this in PDF content)
133
Danese MD, Kim J, Doan QV et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006;47(1):149-156
(check this in PDF content)
134
Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000;36(6):1115-1121
(check this in PDF content)
135
Ishii H, Wada M, Furuya Y et al. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low- turnover bone and osteomalacia. Bone 2000;26(2):175-182
(check this in PDF content)
136
Price PA, Roublick AM, Williamson MK. Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 2006;70(9):1577-1583
(check this in PDF content)
137
Coen G, Manni M, Mantella D et al. Are PTH serum levels predictive of coronary calcifications in haemodialysis patients? Nephrol Dial Transplant 2007;22(11):3262-3267
(check this in PDF content)
138
Neves KR, Graciolli FG, dos Reis LM et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 2007;71(12):1262-1270
(check this in PDF content)
139
Henley C, Colloton M, Cattley RC et al. 1,25- Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/ Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 2005;20(7):1370-1377
(check this in PDF content)
140
Lopez I, Mendoza FJ, Aguilera-Tejero E et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008;73(3):300-307
(check this in PDF content)
141
Rodriguez M, Aguliera-Tejero E, Mendoza FJ et al. Effects of calcimimetics on extraskeletal calcifications in chronic kidney disease. Kidney Int 2008;74(Suppl 111):s50- s54
(check this in PDF content)
142
Lopez I, Aguilera-Tejero E, Mendoza FJ et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 2006;17(3):795-804
(check this in PDF content)
143
Molostvov G, James S, Fletcher S et al. Extracellular calcium-sensing receptor is functionally expressed in human artery. Am J Physiol Renal Physiol 2007;293(3):F946-955
(check this in PDF content)
144
Wonneberger K, Scofield MA, Wangemann P Evidence for a calcium-sensing receptor in the vascular smooth muscle cells of the spiral modiolar artery. J Membr Biol 2000;175(3):203- 212
(check this in PDF content)
145
Murshed M, Schinke T, McKee MD, Karsenty G. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 2004;165(5):625- 630
(check this in PDF content)
146
Luo G, Ducy P, McKee MD et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997;386(6620):78-81
(check this in PDF content)
147
Koleganova N, Piecha G, Ritz E et al. A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int 2009;75(1):60-71
(check this in PDF content)
148
Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000 29;87(7):E10-17
(check this in PDF content)
149
Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007;72(6):709-715
(check this in PDF content)
150
Moe SM, Reslerova M, Ketteler M et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005; 67(6):2295-2304
(check this in PDF content)
151
Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004;95(11):1046-1057
(check this in PDF content)
152
Demer LL, Tintut Y. Pitting phosphate transport inhibitors against vascular calcification. Circ Res 2006; 98(7): 857-859
(check this in PDF content)
153
Tamura K, Suzuki Y, Matsushita M et al. Prevention of aortic calcification by etidronate in the renal failure rat model. Eur J Pharmacol 2007;558(1-3):159-166
(check this in PDF content)
154
Li X, Yang HY, Giachelli CM. Role of the sodium- dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006;98(7):905-912
(check this in PDF content)
155
Shiraishi N, Kitamura K, Miyoshi T et al. Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 2006;48(1):151-154
(check this in PDF content)
156
Cicone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 2004;43(6):1104-1108
(check this in PDF content)
157
Meissner M, Bauer R, Beier C et al. Sodium thiosulphate as a promising therapeutic option to treat calciphylaxis. Dermatology 2006;212(4):373-376
(check this in PDF content)
158
Brucculeri M, Cheigh J, Bauer G, Serur D. Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis. Semin Dial 2005;18(5):431-434
(check this in PDF content)
159
Guerra G, Shah RC, Ross EA. Rapid resolution of calciphylaxis with intravenous sodium thiosulfate and continuous venovenous haemofiltration using low calcium replacement fluid: case report. Nephrol Dial Transplant 2005;20(6):1260- 1262
(check this in PDF content)
160
Velasco N, MacGregor MS, Innes A, MacKay IG. Successful treatment of calciphylaxis with cinacalcet-an alternative to parathyroidectomy? Nephrol Dial Transplant 2006; 21(7):1999-2004
(check this in PDF content)
161
Гавриленков ПВ. Особенности фосфорно-кальци­ евого обмена у больных хронической почечной недостаточ­ ностью, получающих лечение хроническим гемодиализом. Дисс. ...канд. мед. наук. - СПб, 2002
(check this in PDF content)
162
Zerbi S, Ruggiero P, Pedrini LA. Massive soft tissue calcifications and cinacalcet. J Clin Endocrinol Metab 2008; 93(4):1121-1122
(check this in PDF content)
163
Ohanian J, Gatfield KM, Ward DT, Ohanian V. Evidence for a functional calcium-sensing receptor that modulates myogenic tone in rat subcutaneous small arteries. Am J Physiol Heart Circ Physiol 2005;288(4):H1756-1762
(check this in PDF content)
164
Ortiz-Capisano MC, Ortiz PA, Garvin JL et al. Expression and function of the calcium-sensing receptor in juxtaglomerular cells. Hypertension 2007;50(4):737-743
(check this in PDF content)
165
Verdecchia P, Angeli F, Mazzotta G et al. The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vasc Health Risk Manag 2008;4(5):971-981
(check this in PDF content)
166
Smajilovic S, Sheykhzade M, Holmegard HN et al. Calcimimetic, AMG 073, induces relaxation on isolated rat aorta. Vascul Pharmacol 2007;47(4):222-228
(check this in PDF content)
167
Ziegelstein RC, Xiong Y, He C, Hu Q. Expression of a functional extracellular calcium-sensing receptor in human aortic endothelial cells. Biochem Biophys Res Commun 2006; 342(1):153-163
(check this in PDF content)
168
Odenwald T, Nakagawa K, Hadtstein C et al. Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats. J Am Soc Nephrol 2006;17(3):655- 662
(check this in PDF content)
169
Nyirenda MJ, Padfield PL. Parathyroid hormone and hypertension. J Hypertens 2005;23(9):1633-1634
(check this in PDF content)
170
LindbergJS. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease. Kidney Int Suppl 2005; (95):S33-S36
(check this in PDF content)
171
Akmal M, Kasim SE, Soliman AR, Massry SG. Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int 1990;37(3):854-858
(check this in PDF content)
172
Klin M, Smogorzewski M, Ni Z et al. Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest 1996;97(10):2167-2173
(check this in PDF content)
173
Roullet JB, Lacour B, Yvert JP, Drueke T. Correction by insulin of disturbed TG-rich LP metabolism in rats with chronic renal failure. Am J Physiol 1986;250(4 Pt 1):E373-376
(check this in PDF content)
174
Chertow GM, Pupim LB, Block GA et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol 2007; 2(5):898-905
(check this in PDF content)
175
Ogata H, Ritz E, Odoni G et al. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 2003;14(4):959-967
(check this in PDF content)
176
Massfelder T, Parekh N, Endlich K et al. Effect of intrarenally infused parathyroid hormone-related protein on renal blood flow and glomerular filtration rate in the anaesthetized rat. Br J Pharmacol 1996;118(8):1995-2000
(check this in PDF content)
177
Lau K. Phosphate excess and progressive renal failure: the precipitation-calcification hypothesis. Kidney Int 1989; 36(5): 918-937
(check this in PDF content)
178
Khan SR. Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin Exp Nephrol 2004;8(2):75-88
(check this in PDF content)
179
Pattaragarn A, Fox J, Alon US. Effect of the calcimimetic NPS R-467 on furosemide-induced nephrocalcinosis in the young rat. Kidney Int 2004;65(5):1684-1689
(check this in PDF content)
180
Schwarz U, Amann K, Orth SR et al. Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 1998;53(6):1696-1705
(check this in PDF content)
181
Agarwal R, Acharya M, Tian J et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005;68(6):2823-2828
(check this in PDF content)
182
Piecha G, Kokeny G, Nakagawa K et al. Calcimimetic R-568 or calcitriol: equally beneficial on progression of renal damage in subtotally nephrectomized rats. Am J Physiol Renal Physiol 2008;294(4):F748-57
(check this in PDF content)
183
Смирнов АВ, Волков ММ, Добронравов ВА. Карди- опротективные эффекты D-гормона: обзор литературы и собственные данные. Нефрология 2009;13(1):
(check this in PDF content)
184
Смирнов АВ, Волков ММ. Роль витамина D в за­ медлении прогрессирования хронической болезни почек. Нефрология 2008;12(4):20-27
(check this in PDF content)
185
Ishimura E, Nishizawa Y, Inaba M et al. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25- hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 1999;55(3):1019-1027
(check this in PDF content)
186
Martin KJ, Gonzalez EA, Gellens M et al. 19-Nor-1- alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998;9(8):1427-1432
(check this in PDF content)
187
Berl T, Berns AS, Hufer WE et al. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double­ blind controlled study. Ann Intern Med 1978;88(6):774-780
(check this in PDF content)
188
Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol 1999;277(2 Pt 2):F157-175
(check this in PDF content)
189
Khajehdehi P, Taheri S. Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate. J Ren Nutr 2003;13(2):78-83
(check this in PDF content)
190
Koshikawa S, Akizawa T, Kurokawa K et al. Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. A double-blind study among 4 doses. Nephron 2002;90(4):413-423
(check this in PDF content)
191
Moe SM, Zekonis M, Harezlak J et al. A placebo- controlled trial to evaluate immunomodulatory effects of paricalcitol. Am J Kidney Dis 2001;38(4):792-802
(check this in PDF content)
192
Akizawa T, Ohashi Y, Akiba T et al. Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism. Ther Apher Dial 2004;8(6):480-491
(check this in PDF content)
193
Goodman WG. Recent developments in the management of secondary hyperparathyroidism. Kidney Int 2001; 59(3):1187-1201
(check this in PDF content)
194
Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39(4):695-701
(check this in PDF content)
195
Malluche HH, Monier-Faugere MC, Koszewski NJ. Use and indication of vitamin D and vitamin D analogues in patients with renal bone disease. Nephr Dial Transpl 2002;17 (suppl 10):6-9
(check this in PDF content)
196
Matias PJ, Ferreira C, Jorge C et al. 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrol Dial Transplant 2009; 24(2): 611-618
(check this in PDF content)
197
Martin KJ, Gonzalez EA. Vitamin D analogues for the management of secondary hyperparathyroidism. Am J Kidney Dis 2001;38(5 Suppl 5):S34-40
(check this in PDF content)
198
Takahashi F, Finch JL, Denda M et al. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content. Am J Kidney Dis 1997; 30(1):105-112
(check this in PDF content)
199
Sprague SM, Llach F, Amdahl M et al. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63(4):1483-1490
(check this in PDF content)
200
Cunningham J. Achieving therapeutic targets in the treatment of secondary hyperparathyroidism. Nephrol Dial Transplant 2004;19 Suppl 5:V9-14
(check this in PDF content)
201
Gonzalez M, Hutchison A, Girndt M et al. Secondary hyperparathyroidism (HPT) in patients receiving peritoneal dialysis (PD) can be effectively managed with cinacalcet (Mimpara/Sensipar). [Abstract SP359]. Presented at: ERA- EDTA Congress, 15-18 July 2006, Glasgow, UK
(check this in PDF content)
202
Messa P, Villa G, Braun J et al. The OPTIMA study: lower doses of cinacalcet (Mimpara/Sensipar) are required to achieve KDOQI secondary hyperparathyroidism (HPT) targets in patients with less severe disease. [Abstract and Presentation MP324]. Presented at: ERA-EDTA Congress, 15-18 July 2006, Glasgow, UK
(check this in PDF content)
203
Wilkie M, Salvadori M, De Meester J et al. The OPTIMA study: optimising the dose of vitamin D (vit D) in the presence of cinacalcet (Mimpara/Sensipar) to obtain maximum clinical benefit. [Abstract SP358]. Presented at: ERA-EDTA Congress, 15-18 July 2006, Glasgow, UK
(check this in PDF content)
204
Locatelli F, Macario F, Brink H et al. The OPTIMA study; efficacy of cinacalcet (Mimpara/Sensipar) treatment algorithm to treat dialysis patients with elevated PTH and calcium- phosphorus product (Ca x P). [Abstract SP357]. Presented at: ERA-EDTA Congress, 15-18 July 2006, Glasgow, UK
(check this in PDF content)
205
Messa P, Sindici C, Cannella G et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int 1998;54(5):1704-1713
(check this in PDF content)
206
Bonarek H, Merville P, Bonarek M et al. Reduced parathyroid functional mass after successful kidney transplantation. Kidney Int 1999;56(2):642-649
(check this in PDF content)
207
Evenepoel P, Naesens M, Claes K et al. Tertiary ‘hyperphosphatoninism’ accentuates hypophosphatemia and suppresses calcitriol levels in renal transplant recipients. Am J Transplant 2007;7(5):1193-200
(check this in PDF content)
208
Evenepoel P, Claes K, Kuypers D et al. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant 2004;19(5):1281-1287
(check this in PDF content)
209
Reinhardt W, Bartelworth H, Jockenhovel F et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant 1998;13(2):436- 442
(check this in PDF content)
210
Ghanekar H, Welch BJ, Moe OW, Sakhaee K. Post­ renal transplantation hypophosphatemia: a review and novel insights. Curr Opin Nephrol Hypertens 2006;15(2):97-104
(check this in PDF content)
211
Heaf JG. Bone disease after renal transplantation. Transplantation 2003;75(3):315-325
(check this in PDF content)
212
Sperschneider H, Stein G. Bone disease after renal transplantation. Nephrol Dial Transplant 2003;18(5):874- 877
(check this in PDF content)
213
Gwinner W, Suppa S, Mengel M et al. Early calcification of renal allografts detected by protocol biopsies: causes and clinical implications. Am J Transplant 2005;5(8):1934-1941
(check this in PDF content)
214
Serra AL, Savoca R, Huber AR et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant 2007;22(2):577-583
(check this in PDF content)
215
Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. Nephrol Dial Transplant 2007;22(8):2362-2365
(check this in PDF content)
216
Srinivas TR, Schold JD, Womer KL et al. Improvement in hypercalcemia with cinacalcet after kidney transplantation. Clin J Am Soc Nephrol 2006;1(2):323-326
(check this in PDF content)
217
Leca N, Laftavi M, Gundroo A et al. Early and severe hyperparathyroidism associated with hypercalcemia after renal transplant treated with cinacalcet. Am J Transplant 2006; 6(10): 2391-2395
(check this in PDF content)
218
El-Amm JM, Doshi MD, Singh A et al. Preliminary experience with cinacalcet use in persistent secondary hyperparathyroidism after kidney transplantation. Transplantation 2007;83(5):546-549
(check this in PDF content)
219
Szwarc I, Argiles A, Garrigue V et al. Cinacalcet chloride is efficient and safe in renal transplant recipients with posttransplant hyperparathyroidism. Transplantation 2006; 82(5):675-680
(check this in PDF content)
220
Bergua C, Torregrosa JV, Cofan F, Oppenheimer F. Cinacalcet for the treatment of hypercalcemia in renal transplanted patients with secondary hyperparathyroidism. Transplant Proc 2007;39(7):2254-2255
(check this in PDF content)
221
Borchhardt KA, Heinzl H, Mayerwoger E et al. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation 2008;86(7):919-924
(check this in PDF content)
222
Brown EM, Hebert SC. Calcium-receptor-regulated parathyroid and renal function. Bone 1997;20(4):303-309
(check this in PDF content)
223
Bergua C, Torregrosa JV, Fuster D et al. Effect of cinacalcet on hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism. Transplantation 2008;86(3):413-417
(check this in PDF content)
224
Falck P, Vethe NT, Asberg A et al. Cinacalcet’s effect on the pharmacokinetics of tacrolimus, cyclosporine and mycophenolate in renal transplant recipients. Nephrol Dial Transplant 2008;23(3):1048-1053
(check this in PDF content)
225
Schwarz A, Rustien G, Merkel S et al. Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant 2007;22(2):584-591
(check this in PDF content)
226
Evenepoel P, Claes K, Kuypers DR et al. Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrol Dial Transplant 2007;22(6):1730- 1737
(check this in PDF content)
227
Thervet E, Legendre C, Beaune P, Anglicheau D. Cytochrome P450 3A polymorphisms and immunosuppressive drugs. Pharmacogenomics 2005;6(1):37-47
(check this in PDF content)
228
Charytan C, Coburn JW, Chonchol M et al. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis 2005;46(1):58-67
(check this in PDF content)
229
Chonchol M, Locatelli F, Abboud HE et al. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Participants With CKD Not Receiving Dialysis. Am J Kidney Dis 2008 Dec 23. [Epub ahead of print]
(check this in PDF content)